Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard P Tobin

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Cell Death & Disease|March 8, 2024
MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockadeNabanita Mukherjee, Elizabeth Katsnelson, Tonya M Brunetti, et al.
Journal of Nutrition and Metabolism|June 18, 2016
Vitamin D3 Suppresses Class II Invariant Chain Peptide Expression on Activated B-Lymphocytes: A Plausible Mechanism for Downregulation of Acute Inflammatory ConditionsOmar K Danner, Leslie R Matthews, Sharon Francis, et al.
Therapeutic Advances in Medical Oncology|June 27, 2025
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival updateJessica S W Borgers, Theresa M Medina, William A Robinson, et al.
Clinical Science (London, England : 1979)|June 24, 2017
Depletion of MHC class II invariant chain peptide or γ-δ T-cells ameliorates experimental preeclampsiaPiyali Chatterjee, Valorie L Chiasson, Geetha Seerangan, et al.
Cancers|May 14, 2022
BRAF Modulates Lipid Use and AccumulationJacqueline A Turner, Emily L Paton, Robert Van Gulick, et al.
The Journal of Investigative Dermatology|December 23, 2021
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 MimeticsNabanita Mukherjee, Chiara R Dart, Carol M Amato, et al.
Nature Communications|June 3, 2023
Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunityJacqueline A Turner, Malia A Fredrickson, Marc D'Antonio, et al.
Cancers|August 9, 2020
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced MelanomaNabanita Mukherjee, Carol M Amato, Jenette Skees, et al.
Immunohorizons|February 20, 2020
High-Dimensional Analysis of Postsplenectomy Peripheral Immune Cell ChangesJessica S W Borgers, Richard P Tobin, Victoria M Vorwald, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Cell Death & Disease|March 8, 2024
MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockadeNabanita Mukherjee, Elizabeth Katsnelson, Tonya M Brunetti, et al.
Journal of Nutrition and Metabolism|June 18, 2016
Vitamin D3 Suppresses Class II Invariant Chain Peptide Expression on Activated B-Lymphocytes: A Plausible Mechanism for Downregulation of Acute Inflammatory ConditionsOmar K Danner, Leslie R Matthews, Sharon Francis, et al.
Therapeutic Advances in Medical Oncology|June 27, 2025
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival updateJessica S W Borgers, Theresa M Medina, William A Robinson, et al.
Clinical Science (London, England : 1979)|June 24, 2017
Depletion of MHC class II invariant chain peptide or γ-δ T-cells ameliorates experimental preeclampsiaPiyali Chatterjee, Valorie L Chiasson, Geetha Seerangan, et al.
Cancers|May 14, 2022
BRAF Modulates Lipid Use and AccumulationJacqueline A Turner, Emily L Paton, Robert Van Gulick, et al.
The Journal of Investigative Dermatology|December 23, 2021
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 MimeticsNabanita Mukherjee, Chiara R Dart, Carol M Amato, et al.
Nature Communications|June 3, 2023
Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunityJacqueline A Turner, Malia A Fredrickson, Marc D'Antonio, et al.
Cancers|August 9, 2020
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced MelanomaNabanita Mukherjee, Carol M Amato, Jenette Skees, et al.
Immunohorizons|February 20, 2020
High-Dimensional Analysis of Postsplenectomy Peripheral Immune Cell ChangesJessica S W Borgers, Richard P Tobin, Victoria M Vorwald, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Pageof 4